Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel S Parker

Showing results (1-10 of 231) with videos related to

Pageof 24
Sort By:
Cancer Cell|August 13, 2015
Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest?Joel S Parker, Charles M Perou
Bioinformatics (Oxford, England)|January 17, 2019
Improved indel detection in DNA and RNA via realignment with ABRA2Lisle E Mose, Charles M Perou, Joel S Parker
Methods in Enzymology|August 28, 2007
Microarray analysis of miRNA gene expressionJ Michael Thomson, Joel S Parker, Scott M Hammond
Clinical and Translational Gastroenterology|April 30, 2026
Replication of endotypes in eosinophilic esophagitis using a curated gene panel compared to bulk sequencing and assessing stability over timeEvan S Dellon, Yihsuan S Tsai, Joel S Parker, et al.
BMC Genomics|March 5, 2016
Identification of mRNA isoform switching in breast cancerWei Zhao, Katherine A Hoadley, Joel S Parker, et al.
Cancer Immunology Research|November 12, 2020
Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti-PD-1 TherapyDante S Bortone, Mark G Woodcock, Joel S Parker, et al.
European Urology|July 20, 2014
Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84W Kimryn Rathmell, Samira A Brooks, Joel S Parker, et al.
Genetic Epidemiology|July 12, 2002
Symbolic discriminant analysis of microarray data in autoimmune diseaseJason H Moore, Joel S Parker, Nancy J Olsen, et al.
Environmental Health Perspectives|December 16, 2004
Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell linesMelissa A Troester, Katherine A Hoadley, Joel S Parker, et al.
Plos One|October 16, 2010
Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancerAaron R Thorner, Joel S Parker, Katherine A Hoadley, et al.
Pageof 24

Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
Cancer Cell|August 13, 2015
Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest?Joel S Parker, Charles M Perou
Bioinformatics (Oxford, England)|January 17, 2019
Improved indel detection in DNA and RNA via realignment with ABRA2Lisle E Mose, Charles M Perou, Joel S Parker
Methods in Enzymology|August 28, 2007
Microarray analysis of miRNA gene expressionJ Michael Thomson, Joel S Parker, Scott M Hammond
Clinical and Translational Gastroenterology|April 30, 2026
Replication of endotypes in eosinophilic esophagitis using a curated gene panel compared to bulk sequencing and assessing stability over timeEvan S Dellon, Yihsuan S Tsai, Joel S Parker, et al.
BMC Genomics|March 5, 2016
Identification of mRNA isoform switching in breast cancerWei Zhao, Katherine A Hoadley, Joel S Parker, et al.
Cancer Immunology Research|November 12, 2020
Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti-PD-1 TherapyDante S Bortone, Mark G Woodcock, Joel S Parker, et al.
European Urology|July 20, 2014
Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84W Kimryn Rathmell, Samira A Brooks, Joel S Parker, et al.
Genetic Epidemiology|July 12, 2002
Symbolic discriminant analysis of microarray data in autoimmune diseaseJason H Moore, Joel S Parker, Nancy J Olsen, et al.
Environmental Health Perspectives|December 16, 2004
Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell linesMelissa A Troester, Katherine A Hoadley, Joel S Parker, et al.
Plos One|October 16, 2010
Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancerAaron R Thorner, Joel S Parker, Katherine A Hoadley, et al.
Pageof 24